Endocrine Abstracts

Background: The peptide receptor radionuclide therapy (PRRT) is recommended for somatostatin receptors (SSTR) positive neuroendocrine tumors (NET). However, complete remissions with PRRT remain anecdotal and NET patients with low SSTR-positivity are excluded from this treatment. Hence, any approach to increase SSTR2 expression can improve therapeutic efficacy of PRRT. Based on previous in vitro studies with NET cell lines, we hypothesize that a treatm...